irbejub h (irbesartan and hydrochlorothiazide tablets 150 mg+12.5 mg)
pharmaniaga marketing sdn bhd - irbesartan; hydrochlorothiazide* ph. eur -
irbejub h (irbesartan and hydrochlorothiazide tablets 300 mg+12.5 mg)
pharmaniaga marketing sdn bhd - irbesartan; hydrochlorothiazide* ph. eur -
irbejub h (irbesartan and hydrochlorothiazide tablets 300 mg+25 mg)
pharmaniaga marketing sdn bhd - irbesartan; hydrochlorothiazide* ph. eur -
amlotan 5 mg tablet
athlone laboratories ltd - amlodipine (as amlodipine besilate ph. eur.) - tablet - 5 milligram(s) - dihydropyridine derivatives; amlodipine
amlotan 10 mg tablet
athlone laboratories ltd - amlodipine (as amlodipine besilate ph. eur.) - tablet - 10 milligram(s) - dihydropyridine derivatives; amlodipine
istin 5mg tablets
pfizer healthcare ireland - amlodipine (as amlodipine besilate ph. eur.) - tablet - 5 milligram(s) - dihydropyridine derivatives; amlodipine
flucloxacillin 125 mg/5 ml powder for oral solution, sugar free
brillpharma (ireland) limited - flucloxacillin sodium ph. eur. - powder for oral solution - 125 mg/5ml - beta-lactamase resistant penicillins; flucloxacillin
flucloxacillin 250 mg/5 ml powder for oral solution, sugar free
brillpharma (ireland) limited - flucloxacillin sodium ph. eur. - powder for oral solution - 250 mg/5ml - beta-lactamase resistant penicillins; flucloxacillin
ekosonic mach4 endovascular device - ultrasound thrombolysis system pulmonary artery catheter
boston scientific pty ltd - 59223 - ultrasound thrombolysis system pulmonary artery catheter - high frequency low power ultrasound facilitates the delivery of thrombolytics into the pulmonary embolism through an intelligent drug delivery catheter and microsonic device connected to a control unit which deliver the thrombolytics and ultrasound to the treatment site.the control unit generates ultrasonic waves which emanate radially from the treatment zone into and through the blood, thrombus or tissue surrounding the treatment zone with the patients pulmonary embolism. intended for the treatment of pulmonary embolism patients with >/= 50% clot burden in one or both main pulmonary arteries or lobar pulmonary arteries , and evidence of right heart dysfunction based on right heart pressures(mean pulmonary artery pressure >/= 25 mmhg) or echocardiographic evaluation.
red and white cell metabolic enzyme and haemolysis ivds
abbott rapid diagnostics pty ltd - ct881 - red and white cell metabolic enzyme and haemolysis ivds - ivds intended for qualitative detection of g6pd enzyme activity in clinical specimens.